Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

被引：2
|
作者：
Miaris, Nikolaos [1 ]
Sgouros, Joseph [1 ]
Gerolympou, Margarita [1 ]
Spyropoulos, Basilios [2 ]
Drakopoulos, Dionysios [3 ]
Gkoura, Stefania [1 ]
Res, Helen [1 ]
Samantas, Epaminondas [1 ]
机构：
[1] Agioi Anargyroi Gen Oncol Hosp Kifisia, Dept Med Oncol 3, Noufaron & Timiou Stavrou 14, Athens 14564, Greece
[2] 401 Gen Mil Hosp Athens, Dept Internal Med 1, Athens, Greece
[3] 401 Gen Mil Hosp Athens, Dept Radiol, Athens, Greece
来源：
JOURNAL OF GASTROINTESTINAL CANCER | 2019年 / 50卷 / 01期
关键词：
LEUKOENCEPHALOPATHY SYNDROME; OXALIPLATIN;
D O I：
10.1007/s12029-017-9986-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：123 / 126
页数：4
相关论文
共 50 条
  • [41] Identification of Predictive Markers of Response to 5-Fluorouracil and Irinotecan in Metastatic Colorectal Cancer
    Coyle, Vicky M.
    Allen, Wendy L.
    Boyer, John
    McLean, Estelle
    McCulla, Andrea
    Longley, Daniel B.
    Johnston, Patrick G.
    CANCER RESEARCH, 2006, 66 (08)
  • [42] Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer
    Lemmens, J
    Berteloot, P
    Thomas, J
    Wildiers, J
    Paridaens, R
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) : 2114 - 2115
  • [43] Posterior Reversible Encephalopathy Syndrome After 5-Fluorouracil Therapy for Colon Cancer Presenting as Status Epilepticus
    Pansare, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [44] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)
    Ding, Hong-hua
    Wu, Wei-dong
    Jiang, Tao
    Cao, Jun
    Ji, Zheng-yi
    Jin, Jia-huan
    Wang, Jing-jue
    Song, Wei-feng
    Wang, Li-wei
    TUMOR BIOLOGY, 2015, 36 (05) : 3361 - 3369
  • [46] Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients
    Baba, Eishi
    Fujishima, Hiromitsu
    Makiyama, Akitaka
    Uchino, Keita
    Tanaka, Risa
    Esaki, Taito
    Kusaba, Hitoshi
    Mitsugi, Kenji
    Nakano, Shuji
    Akashi, Koichi
    ADVANCES IN THERAPY, 2012, 29 (03) : 287 - 296
  • [47] Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients
    Eishi Baba
    Hiromitsu Fujishima
    Akitaka Makiyama
    Keita Uchino
    Risa Tanaka
    Taito Esaki
    Hitoshi Kusaba
    Kenji Mitsugi
    Shuji Nakano
    Koichi Akashi
    Advances in Therapy, 2012, 29 : 287 - 296
  • [48] Irinotecan combined with leucovorin-5-fluorouracil in the treatment of advanced colorectal cancer.
    Rigatos, SK
    Stathopoulos, GP
    Nacos, A
    Stathopoulos, J
    Pergantas, N
    Athanassiadis, I
    ANNALS OF ONCOLOGY, 2000, 11 : 56 - 56
  • [49] A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer
    Li, Qiu
    Chen, Jing
    Zhao, Xin
    Yin, Xude
    Mei, Kai
    Zhou, Chengya
    Cai, Xiaohong
    TUMORI JOURNAL, 2009, 95 (04): : 432 - 437
  • [50] Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
    Arkenau, Hendrik-Tobias
    Graeven, Ullrich
    Kubicka, Stephan
    Grothey, Axel
    Englisch-Fritz, Christina
    Kretzschmar, Albrecht
    Greil, Richard
    Freier, Werner
    Seufferlein, Thomas
    Hinke, Axel
    Schmoll, Hans-Joachim
    Schmiegel, Wolff
    Porschen, Rainer
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 60 - 64
12345